AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharmaceutical Companies

650.237

-4.347-0.66%

Number of Gainers:15

Number of Losers:10

Number of Flat:20

PE:- -

High:656.360

Open:654.803

Low:647.137

Close:654.584

Volume:32.54M

Turnover:84.95M

Market Cap:97.22B

Float Cap:94.17B

Loading ...

Haemonetics reports second quarter revenue of $327 million and earnings per diluted share of $0.81

BRIEF-Australian Government Takeovers Panel Receives Application From Mayne Pharma

Australia's Takeovers Panel - No Decision Has Been Made Whether to Conduct Proceedings

THOMSON REUTERS

Australia's Takeovers Panel - Mayne Seeks Final Orders, Including Cosette Agree to Extend Statutory Deadline for Firb's Determination to 1 Dec

THOMSON REUTERS

Australian Govt Takeovers Panel - Receives Application From Mayne Pharma Group

THOMSON REUTERS

Australia's Takeovers Panel - Mayne Seeks Interim Orders, Including Cosette Confirm to the Panel That It Will Meet With Firb

THOMSON REUTERS

Proteomics International Receives AU$500,000 Western Australia Grant to Help Commercialize Endometriosis Blood Test

MT Newswires Live

Proteomics International Laboratories Ltd - All Figures in AUD

THOMSON REUTERS

Orthocell Reports Sixth Consecutive Quarter of Record Revenue in September Quarter

MT Newswires Live

BRIEF-Neuren Pharmaceuticals Posts Record Daybue™ Net Sales Of US$101.1 Million In Q3

BUZZ-Australia's Neuren Pharma at more than 2-month-low on revising royalty outlook

Immuron Ltd-Proposed Issue of Securities - Imc

THOMSON REUTERS

Neuren Pharmaceuticals Ltd - Record Daybue™ Net Sales of US$101.1 Mln in Q3

THOMSON REUTERS

Supreme Court has a packed house for Trump tariffs case amid shutdown

Monash IVF Group Ltd-Non-Executive Director Appointment - Mr Dwayne Crombie

THOMSON REUTERS

Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

MT Newswires Live

BRIEF-Immuron Says IMM-529 IND Approved By FDA

FDA Approves IND Application for Immuron’s IMM-529 to Treat C. difficile Infection

Immuron Ltd - Plans Phase 2 Trial for Imm-529 in First Half of 2026

THOMSON REUTERS

BRIEF-CSL Ltd Sees High Single-Digit NPAT Growth Beyond FY26

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK7508/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":650.2372,"timestamp":1762745474781,"preClose":654.584,"halted":0,"volume":32537257,"delay":0,"changeRate":-0.006641,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-4.346802,"latestTime":"11-10 14:31:15 AEDT","open":654.80316,"high":656.3603,"low":647.13666,"amount":84948487,"amplitude":0.014091,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1762750800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1762729200000,1762750800000]],"turnoverRate":0.001249,"increases":16,"decrements":10,"flats":18,"marketCap":97217885681.5,"floatMarketCap":94165918138.625},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":656.3603,"amplitude":0.014091,"preClose":654.584,"low":647.13666,"latestPrice":650.2372,"volume":32537257,"delay":0,"open":654.80316,"prevYearClose":936.801,"prevWeekClose":654.584,"prevMonthClose":662.953,"prevQuarterClose":712.826,"fiveDayClose":650.95,"twentyDayClose":751.072,"sixtyDayClose":937.392,"secType":"PLATE","market":"AU","turnoverRate":0.001249,"marketCap":97217885681.5,"floatMarketCap":94165918138.625,"timestamp":1762745474781,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":15,"down":10,"flat":20},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2581065005","title":"Haemonetics reports second quarter revenue of $327 million and earnings per diluted share of $0.81","url":"https://stock-news.laohu8.com/highlight/detail?id=2581065005","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581065005?lang=en_us&edition=fundamental","pubTime":"2025-11-06 19:01","pubTimestamp":1762426885,"startTime":"0","endTime":"0","summary":"Haemonetics Corporation reported second quarter fiscal 2026 revenue of $327 million, a decrease of 5.0 percent compared to the prior year period. Year-to-date revenue was $649 million, also down 5.0 percent. Organic revenue decreased by 1.8 percent in the quarter and 0.7 percent year-to-date. Excluding CSL, organic revenue increased by 9.4 percent in the quarter and 11.1 percent year-to-date. Earnings per diluted share were $0.81 for the quarter and $1.51 year-to-date. Adjusted earnings per diluted share were $1.27 for the quarter and $2.36 year-to-date. The company raised its total company fiscal 2026 guidance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Haemonetics Corporation published the original content used to generate this n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL6TM5md:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z6F94.USD","CSL.AU","LU1169589451.USD","IE00BLDYK493.USD","IE0034390439.USD","LU1169590202.USD","HAE","LU0205194284.USD","BK7508","LU0106261612.USD","BK4198","LU0205193047.USD","LU0012050646.USD","BK7511","BK7067","BK7501","IE00B64QTZ34.USD"],"gpt_icon":0},{"id":"2581063159","title":"BRIEF-Australian Government Takeovers Panel Receives Application From Mayne Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2581063159","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581063159?lang=en_us&edition=fundamental","pubTime":"2025-11-06 18:29","pubTimestamp":1762424987,"startTime":"0","endTime":"0","summary":"BRIEF-Australian Government Takeovers Panel Receives Application From Mayne PharmaNov 6  - Australian Government Takeovers Panel:TOV: MYX PANEL RECEIVES APPLICATION,TOVRECEIVES APPLICATION FROM MAYNE PHARMA GROUPSITTING PANEL HAS NOT BEEN APPOINTED AT THIS STAGENO DECISION HAS BEEN MADE  WHETHER TO CONDUCT PROCEEDINGSMAYNE SEEKS INTERIM ORDERS, INCLUDING COSETTE CONFIRM TO THE PANEL THAT IT WILL MEET WITH FIRBMAYNE SEEKS FINAL ORDERS, INCLUDING COSETTE AGREE TO EXTEND STATUTORY DEADLINE FOR FIRB'S DETERMINATION TO 1 DECFurther company coverage: MYX.AX ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUE8KMLW1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","MYX.AU","BK7096"],"gpt_icon":0},{"id":"2581905572","title":"Australia's Takeovers Panel - No Decision Has Been Made  Whether to Conduct Proceedings","url":"https://stock-news.laohu8.com/highlight/detail?id=2581905572","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581905572?lang=en_us&edition=fundamental","pubTime":"2025-11-06 15:31","pubTimestamp":1762414276,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUE8KMLW1:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2581091055","title":"Australia's Takeovers Panel - Mayne Seeks Final Orders, Including Cosette Agree to Extend Statutory Deadline for Firb's Determination to 1 Dec","url":"https://stock-news.laohu8.com/highlight/detail?id=2581091055","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581091055?lang=en_us&edition=fundamental","pubTime":"2025-11-06 15:31","pubTimestamp":1762414276,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUE8KMLW1:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","MYX.AU"],"gpt_icon":0},{"id":"2581055783","title":"Australian Govt Takeovers Panel - Receives Application From Mayne Pharma Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2581055783","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581055783?lang=en_us&edition=fundamental","pubTime":"2025-11-06 15:31","pubTimestamp":1762414276,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUE8KMLW1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2581055059","title":"Australia's Takeovers Panel - Mayne Seeks Interim Orders, Including Cosette Confirm to the Panel That It Will Meet With Firb","url":"https://stock-news.laohu8.com/highlight/detail?id=2581055059","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581055059?lang=en_us&edition=fundamental","pubTime":"2025-11-06 15:31","pubTimestamp":1762414276,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUE8KMLW1:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MYX.AU","BK7096"],"gpt_icon":0},{"id":"2581003705","title":"Proteomics International Receives AU$500,000 Western Australia Grant to Help Commercialize Endometriosis Blood Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2581003705","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581003705?lang=en_us&edition=fundamental","pubTime":"2025-11-06 14:29","pubTimestamp":1762410577,"startTime":"0","endTime":"0","summary":"Proteomics International Laboratories  received a AU$500,000 grant from the Western Australian government to accelerate the commercialization of its blood test for the early diagnosis of endometriosis, according to a Thursday Australian bourse filing.The funding was provided by the Western Australian government's Future Health Research and Innovation Fund. It will contribute to commercialization activities, including regulatory engagement, marketing, and partnership development.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["WRN","XKO.AU","BK7048","PIQ.AU","BK7508","XAO.AU","BK4168","XJO.AU"],"gpt_icon":0},{"id":"2581033533","title":"Proteomics International Laboratories Ltd - All Figures in AUD","url":"https://stock-news.laohu8.com/highlight/detail?id=2581033533","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581033533?lang=en_us&edition=fundamental","pubTime":"2025-11-06 10:52","pubTimestamp":1762397523,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUE2HYPVB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","PIQ.AU","BK7048"],"gpt_icon":0},{"id":"2581080774","title":"Orthocell Reports Sixth Consecutive Quarter of Record Revenue in September Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2581080774","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581080774?lang=en_us&edition=fundamental","pubTime":"2025-11-06 10:13","pubTimestamp":1762395236,"startTime":"0","endTime":"0","summary":"Orthocell  said its revenue for the quarter ended Sept. 30 came in at $3 million, its highest result to date and the sixth consecutive quarter of record revenue, according to a Thursday Australian bourse filing.Its revenue for the same period in the previous year was $2 million.The firm is targeting inclusion in the ASX 300 index as part of its three-year vision. It seeks to advance its product pipeline with collagen scaffold applications in musculoskeletal repair, build a nerve repair portfolio, and validate advancements in cell therapy technology.It is also focused on the launch of its Remplir nerve repair product in the US and Canada, as well as the onboarding of \"strategic\" countries in Asia.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OCC.AU","BK7067","BK7508"],"gpt_icon":1},{"id":"2581087623","title":"BRIEF-Neuren Pharmaceuticals Posts Record Daybue™ Net Sales Of US$101.1 Million In Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2581087623","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581087623?lang=en_us&edition=fundamental","pubTime":"2025-11-06 09:29","pubTimestamp":1762392578,"startTime":"0","endTime":"0","summary":"BRIEF-Neuren Pharmaceuticals Posts Record Daybue™ Net Sales Of US$101.1 Million In Q3Nov 6 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX:RECORD DAYBUE™ NET SALES OF US$101.1 MILLION IN Q3Further company coverage: NEU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nFWN3WH2PJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7096","NEU.AU"],"gpt_icon":0},{"id":"2581087325","title":"BUZZ-Australia's Neuren Pharma at more than 2-month-low on revising royalty outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2581087325","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581087325?lang=en_us&edition=fundamental","pubTime":"2025-11-06 09:23","pubTimestamp":1762392203,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neuren Pharma at more than 2-month-low on revising royalty outlook** Neuren Pharmaceuticals NEU.AX slips as much as 11.3% to A$17.95, lowest since August 27; among top losers on S&P/ASX 200 index .AXJO** Biopharma co says Nasdaq-listed Acadia AACD.O narrowed FY25 U.S. net sales outlook for co's Rett syndrome medication, DAYBUE, to $385 mln–400 mln from $380 mln-405 mln** Neuren granted exclusive worldwide licence to Acadia for development, commercialisation of DAYBUE** Outlook revision implies FY25 U.S. royalty income for Neuren seen at A$63 mln -A$66 mln vs A$62 mln-A$67 mln expected earlier** YTD, NEU gains 49.8%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL6N3WI02T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","BK7508","NEU.AU"],"gpt_icon":1},{"id":"2581818250","title":"Immuron Ltd-Proposed Issue of Securities - Imc","url":"https://stock-news.laohu8.com/highlight/detail?id=2581818250","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581818250?lang=en_us&edition=fundamental","pubTime":"2025-11-06 08:06","pubTimestamp":1762387580,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUE8RNV3Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMC.AU"],"gpt_icon":0},{"id":"2581208510","title":"Neuren Pharmaceuticals Ltd - Record Daybue™ Net Sales of US$101.1 Mln in Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2581208510","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581208510?lang=en_us&edition=fundamental","pubTime":"2025-11-06 06:59","pubTimestamp":1762383584,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nFWN3WH2PJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NEU.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2581389700","title":"Supreme Court has a packed house for Trump tariffs case amid shutdown","url":"https://stock-news.laohu8.com/highlight/detail?id=2581389700","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581389700?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:46","pubTimestamp":1762379168,"startTime":"0","endTime":"0","summary":"Supreme Court has a packed house for Trump tariffs case amid shutdownTrump's treasury and commerce secretaries in attendanceUS government in the midst of a long-running shutdownJustices cast doubt on legality of Trump tariffsBy Blake Brittain","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL6N3WG1QY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMU.AU"],"gpt_icon":0},{"id":"2581020167","title":"Monash IVF Group Ltd-Non-Executive Director Appointment - Mr Dwayne Crombie","url":"https://stock-news.laohu8.com/highlight/detail?id=2581020167","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581020167?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:33","pubTimestamp":1762378407,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nTUE20LPTM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MVF.AU","BK7113","BK7508"],"gpt_icon":0},{"id":"2581722771","title":"Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2581722771","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581722771?lang=en_us&edition=fundamental","pubTime":"2025-11-05 23:41","pubTimestamp":1762357299,"startTime":"0","endTime":"0","summary":"Asian equities traded in the US as American depositary receipts were trending higher Wednesday morning, rising 0.51% to 2,703.37 on the S&P Asia 50 ADR Index.From North Asia, the gainers were led by solar panel maker JinkoSolar  and computer hardware maker Canaan , which climbed 8.7% and 7.7% respectively. They were followed by mobile big data platform Aurora Mobile  and used car marketplace Uxin , which advanced 7.3% and 5.1% respectively.The decliners from North Asia were led by lender CNFinance  and fintech firm Maase , which fell 5.5% and 4.3% respectively. They were followed by media company Phoenix New Media  and technology and real-estate company Eason Technology , which were down 3.5% and 3.1% respectively.From South Asia, the gainers were led by IT firm Sify Technologies  and telecommunication operator Telekomunikasi Indonesia , which rose 2.1% and 1.6% respectively. They were followed by tech conglomerate Sea  and IT firm Wipro , which were up 1.4% and 1% respectively.The onl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4085","RDY.AU","LU0572939691.SGD","BK4563","JKS","SG9999013460.SGD","TLK","LU0516423091.SGD","CNF","DXF","FENG","LU0210637038.USD","RDY","LU0541502299.USD","AFG","BK4581","BK4532","JG","LU0197229882.USD","UXIN","SG9999002679.SGD","BK4214","BK4135","BK4519","LU0264606111.USD","LU0345775950.USD","LU1805238398.USD","IE00BD6J9T35.USD","WIT","CAN","LU0289960550.SGD","BK4173","SIFY","SG9999013478.USD","BK4122","LU0261945553.USD","LU0348814723.USD","LU2663582299.SGD","MAAS","BK7508","LU1804176565.USD","LU0918141887.USD","HDB","LU0516422366.SGD","LU0541501648.USD","BK4089","CAN.AU","LU1508157978.USD","BK4526"],"gpt_icon":1},{"id":"2581251697","title":"BRIEF-Immuron Says IMM-529 IND Approved By FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2581251697","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581251697?lang=en_us&edition=fundamental","pubTime":"2025-11-05 19:25","pubTimestamp":1762341936,"startTime":"0","endTime":"0","summary":"BRIEF-Immuron Says IMM-529 IND Approved By FDANov 5 (Reuters) - Immuron Ltd IMC.AX:IMM-529 IND APPROVED BY FDAFurther company coverage: IMC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nFWN3WG1TV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2581272353","title":"FDA Approves IND Application for Immuron’s IMM-529 to Treat C. difficile Infection","url":"https://stock-news.laohu8.com/highlight/detail?id=2581272353","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581272353?lang=en_us&edition=fundamental","pubTime":"2025-11-05 19:00","pubTimestamp":1762340421,"startTime":"0","endTime":"0","summary":"Immuron Limited has announced that the U.S. Food and Drug Administration  has approved its Investigational New Drug  application for IMM-529, allowing the company to proceed with a Phase 2 clinical trial targeting Clostridioides difficile infection . The IND approval enables Immuron to begin clinical development of IMM-529, which is designed to prevent and treat CDI, including recurrent cases. IMM-529 utilizes antibodies derived from hyperimmune bovine colostrum and has demonstrated promising results in pre-clinical models for prevention, protection against recurrence, and treatment of CDI. The Phase 2 trial is expected to start in the first half of 2026. No other organizations were mentioned as recipients of the regulatory approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpret","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL8TFDFF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK7067","NDAQ","IMC.AU","LU2210149790.SGD","IE00BKPKM429.USD","LU2095319765.USD","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BGHQF748.EUR","LU2210150020.SGD","IE00B64PRP62.GBP","BK4112","BK4588","BK7508"],"gpt_icon":0},{"id":"2581872349","title":"Immuron Ltd - Plans Phase 2 Trial for Imm-529 in First Half of  2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2581872349","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581872349?lang=en_us&edition=fundamental","pubTime":"2025-11-05 19:00","pubTimestamp":1762340400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nTUACGMXN0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMC.AU","BK7067"],"gpt_icon":0},{"id":"2581749169","title":"BRIEF-CSL Ltd Sees High Single-Digit NPAT Growth Beyond FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2581749169","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581749169?lang=en_us&edition=fundamental","pubTime":"2025-11-05 16:27","pubTimestamp":1762331238,"startTime":"0","endTime":"0","summary":"BRIEF-CSL Ltd Sees High Single-Digit NPAT Growth Beyond FY26Nov 5  - CSL Ltd CSL.AX:SEES MID SINGLE-DIGIT REVENUE GROWTH BEYOND FY26SEES HIGH SINGLE-DIGIT NPAT GROWTH BEYOND FY26SEES CONTINUED DIVIDENDS AND MULTI-YEAR, ON-MARKET SHARE BUYBACKS BEYOND FY26Further company coverage: CSL.AX ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nFWN3WG24R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","BK7511","CSL.AU","BK7067"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":2,"totalSize":170,"code":"91000000","status":"200"}]}}